Foster City, CA,  February 12, 2024 (Yahoo Finance) -- Gilead Sciences announces acquisition of CymaBay Therapeutics in a $4.3 billion deal. The proposed acquisition will grant Gilead access to an experimental treatment CymaBay's liver disease drug for primary biliary cholangitis.
Read full article here.
NY, NY, April 18, 2024 (Business Wire) -- Metsera, Inc., a pioneering player in the clinical-stage biopharmaceutical realm focusing on innovative treatments for obesity and metabolic ailments, has e
Cambridge, MA, April 23 2024 (PRNewswire) -- Flare Therapeutics Inc. has undergone a notable leadership transition with the selection of Dr. Douglas Manion, M.D., FRCP (C), as its newly appointed Ch
Wilmington, DE, April 23, 2024 (RTTNews) -- Incyte Corp. (INCY) is buying Escient Pharmaceuticals and its assets for $750 million, plus any cash left over when the deal closes. This acquisition need
